Verona Pharma Plc ADR (NASDAQ: VRNA) is 8.33% higher on its value in year-to-date trading and has touched a low of $11.39 and a high of $51.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRNA stock was last observed hovering at around $48.44 in the last trading session, with the day’s gains setting it 1.87%.
Currently trading at $50.31, the stock is 10.53% and 21.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.1 million and changing 3.86% at the moment leaves the stock 89.01% off its SMA200. VRNA registered 180.43% gain for a year compared to 6-month gain of 126.01%. The firm has a 50-day simple moving average (SMA 50) of $41.0534 and a 200-day simple moving average (SMA200) of $26.446625.
The stock witnessed a 28.15% loss in the last 1 month and extending the period to 3 months gives it a 46.85%, and is 1.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.02% over the week and 6.53% over the month.
Verona Pharma Plc ADR (VRNA) has around 79 employees, a market worth around $4.12B and $5.68M in sales. Fwd P/E is 2321.64. Profit margin for the company is -2716.65%. Distance from 52-week low is 341.70% and -2.88% from its 52-week high. The company has generated returns on investments over the last 12 months (-43.62%).
with sales reaching $22.46M over the same period.The EPS is expected to shrink by -540.00% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
195.0 institutions hold shares in Verona Pharma Plc ADR (VRNA), with institutional investors hold 90.59% of the company’s shares. The shares outstanding are 81.83M, and float is at 68.91M with Short Float at 10.01%. Institutions hold 88.91% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 7.63 million shares valued at $110.37 million. The investor’s holdings represent 9.4566 of the VRNA Shares outstanding. As of 2024-06-30, the second largest holder is NEA MANAGEMENT COMPANY, LLC with 5.58 million shares valued at $80.76 million to account for 6.9193 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 4.0 million shares representing 4.9559 and valued at over $57.84 million, while VIVO CAPITAL, LLC holds 4.398 of the shares totaling 3.55 million with a market value of $51.33 million.
Verona Pharma Plc ADR (VRNA) Insider Activity
The most recent transaction is an insider sale by ZACCARDELLI DAVID, the company’s President and CEO. SEC filings show that ZACCARDELLI DAVID sold 640,264 shares of the company’s common stock on Dec 05 ’24 at a price of $5.01 per share for a total of $3.21 million. Following the sale, the insider now owns 14.37 million shares.
Verona Pharma Plc ADR disclosed in a document filed with the SEC on Dec 06 ’24 that ZACCARDELLI DAVID (President and CEO) sold a total of 162,800 shares of the company’s common stock. The trade occurred on Dec 06 ’24 and was made at $5.01 per share for $0.82 million. Following the transaction, the insider now directly holds 14.2 million shares of the VRNA stock.
Still, SEC filings show that on Dec 04 ’24, ZACCARDELLI DAVID (President and CEO) disposed off 67,608 shares at an average price of $5.00 for $0.34 million. The insider now directly holds 15,007,816 shares of Verona Pharma Plc ADR (VRNA).
